Royal London Asset Management Ltd. Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Royal London Asset Management Ltd. trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 81.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 76,557 shares of the medical research company’s stock after selling 338,559 shares during the period. Royal London Asset Management Ltd.’s holdings in IQVIA were worth $15,044,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Synergy Asset Management LLC purchased a new position in IQVIA in the fourth quarter worth approximately $33,000. Avior Wealth Management LLC boosted its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the period. Versant Capital Management Inc boosted its position in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after buying an additional 93 shares during the period. SBI Securities Co. Ltd. purchased a new position in shares of IQVIA during the fourth quarter worth $60,000. Finally, UMB Bank n.a. boosted its position in shares of IQVIA by 72.8% during the fourth quarter. UMB Bank n.a. now owns 401 shares of the medical research company’s stock worth $79,000 after buying an additional 169 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Up 0.9 %

Shares of IQVIA stock opened at $185.85 on Friday. The business has a 50 day moving average price of $194.94 and a 200 day moving average price of $208.45. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $254.54. The company has a market capitalization of $32.77 billion, a P/E ratio of 24.78, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on IQV shares. Truist Financial reiterated a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Bank of America lowered their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.